Navigation Links
Siemens Addresses Cost vs. Value Issues In Healthcare and Technology
Date:4/16/2008

Representatives from Capitol Hill Are Briefed on Challenges Facing the

Healthcare Industry

WASHINGTON, April 16 /PRNewswire-FirstCall/ -- Siemens Healthcare (http://www.siemens.com/healthcare), in association with U.S. News & World Report, hosted an exclusive panel discussion today titled "Health Care and Technology: Cost vs. Value," at the National Press Club in Washington, D.C. The event, attended by Congressional staff, senior business executives, and the press, examined the "value paradigm" between advances in technology and rising healthcare costs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

A diverse panel of experts weighed in on the topics of early and frequent use of imaging in shortening initial clinical evaluation, cost effectiveness and accessibility of imaging, the role of patient education, and lessons in deploying health technology and what the industry can expect to deliver in the near term. The panel also examined practical ways in which government and the healthcare industry can create consistent and generally accepted standards for measuring new technologies, maintaining the quality of procedures while reducing costs, and working together for future healthcare innovation.

"Sooner or later, all of us are patients. So, when we go through these deliberations, it is always helpful to use this to guide our decisions in the future," said Dr. Bernadine Healy, health editor, U.S. News & World Report, who also served as panel moderator for the discussions.

The panel debated how to measure the value of medical imaging and how to best reconcile costs in an era of personalized medicine. The audience also heard from the government panelists on how technology is reviewed for potential funding and the need for evidence develop
'/>"/>

SOURCE Siemens Healthcare
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Siemens Extends Tender Offer for Acquisition of Dade Behring
2. Siemens Congratulates Kenneth R. Bertka, M.D., Recipient of 2007 AMDIS Award
3. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
4. MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners
5. VIDEO from Medialink and Siemens: The Next Generation Allergy Test - Nothing to Sneeze At
6. Siemens Building Technologies Pioneers Wireless Solution for St. Anthonys Sensitive Environment
7. Susquehanna Health and Siemens Announce Plans to Improve Hospital Facilities Through Technology Investment
8. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
9. VIDEO from Medialink and Siemens: Worlds Smallest Ultrasound Package Launches in the U.S.
10. Siemens Soarian Health Information Management is Widely Adopted by Leading Healthcare Institutions in 2007
11. James Cracknell Launches Siemens Stroke for Stroke Week
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4Binge Drinking Not Just a Rite of the Young 62247 1Binge Drinking Not Just a Rite of the Young 62247 2Healing from the Inside Out 3A Compelling New Book Explores the Intricate Connection between Body Soul and Better Health 62245 1Healing from the Inside Out 3A Compelling New Book Explores the Intricate Connection between Body Soul and Better Health 62245 2Baxa to Sponsor ASHP Midday Symposium 3A Creating a Culture of Safety in Pharmacy A Panel Discussion on Lessons Learned 62243 1Baxa to Sponsor ASHP Midday Symposium 3A Creating a Culture of Safety in Pharmacy A Panel Discussion on Lessons Learned 62243 2Baxa to Sponsor ASHP Midday Symposium 3A Creating a Culture of Safety in Pharmacy A Panel Discussion on Lessons Learned 62243 3
Other Medicine Technology:Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 2Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 3Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 4Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 5Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 6Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 7Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 8